Cornercap Investment Counsel Inc. Has $66,000 Stock Holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Cornercap Investment Counsel Inc. reduced its holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 50.4% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 47,763 shares of the company’s stock after selling 48,525 shares during the quarter. Cornercap Investment Counsel Inc.’s holdings in Lyell Immunopharma were worth $66,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. Jacobs Levy Equity Management Inc. bought a new position in Lyell Immunopharma during the 1st quarter worth $64,000. Dimensional Fund Advisors LP increased its stake in shares of Lyell Immunopharma by 197.8% in the second quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock valued at $58,000 after buying an additional 26,635 shares during the period. ProShare Advisors LLC raised its position in shares of Lyell Immunopharma by 9.3% during the first quarter. ProShare Advisors LLC now owns 48,986 shares of the company’s stock worth $109,000 after acquiring an additional 4,170 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Lyell Immunopharma by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company’s stock valued at $68,000 after acquiring an additional 19,287 shares during the last quarter. Finally, SG Americas Securities LLC increased its position in Lyell Immunopharma by 78.1% during the 3rd quarter. SG Americas Securities LLC now owns 57,566 shares of the company’s stock valued at $79,000 after purchasing an additional 25,247 shares during the period. Institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Price Performance

NASDAQ LYEL opened at $1.11 on Tuesday. Lyell Immunopharma, Inc. has a one year low of $0.85 and a one year high of $3.26. The business has a 50 day simple moving average of $1.21 and a 200 day simple moving average of $1.66. The stock has a market capitalization of $309.93 million, a P/E ratio of -1.41 and a beta of -0.47.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.03. The company had revenue of $0.03 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. Equities analysts expect that Lyell Immunopharma, Inc. will post -0.8 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on LYEL shares. HC Wainwright restated a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a research report on Tuesday, November 12th. Bank of America lowered shares of Lyell Immunopharma from a “buy” rating to an “underperform” rating and dropped their target price for the company from $6.00 to $1.00 in a report on Wednesday, October 30th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.